39 results about "Immunoglobulin Constant Region" patented technology

The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

The invention relates to anti viral agents comprised of viral fusion inhibitors and at least a portion of an immunoglobulin constant region. The invention further relates to anti viral agents comprised HIV viral fusion inhibitors and an Fc fragment of an immunoglobulin. The invention also relates to methods of treating a viral infection, including HIV infection.

The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide having an immunoglobulin constant region where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding of the first and second polypeptides to these affinity reagents. The invention also provides bispecific antibodies that have IgG CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding of the IgG regions to these affinity reagents. The invention also concerns bispecific antibodies which are heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least two amino acids that allow for the isolation of the bispecific antibody based on a differential affinity of one mutated immunoglobulin heavy chain and a second mutated immunoglobulin heavy chain toward two different affinity reagents.

Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically, preferably therapeutically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the constant region that results in reduction or loss of FcRn binding but does not cause substantial reduction of serum half-life of said antibody fusion protein. In a preferred embodiment the invention relates to respectively constructed Fc-IFNss molecules. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.

The invention relates to the technical field of biomedical engineering, and provides a composition related to soluble dimeric immunoadherend and a method thereof. The dimeric immunoadhesin comprises afirst dimerized polypeptide chain and a second dimerized polypeptide chain. Wherein a structural general formula of the first polypeptide chain is Z1-Z2, and the structural general formula of the second polypeptide chain is Y1-Y2. Wherein Z1 is (i) an extracellular domain of a first cell surface receptor or a functional variant or fragment thereof, or (ii) a first cytokine or a functional variantor fragment thereof; Z2 is an immunoglobulin constant region dimerization domain or a functional variant or fragment thereof. Y1 is an extracellular domain or a functional variant or fragment thereofof a second cell surface receptor, or (ii) a second cytokine or a functional variant or fragment thereof. Y2 is an immunoglobulin constant region dimerization domain or the functional variant or fragment thereof. The dimer protein can be used for treating and preventing diseases related to infertility.

The present invention provides a method for altering a T cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the Valpha or Vbeta region of a TCR from particular T cells from a patient having a T cell mediated pathology, and an immunoglobulin constant region. The genes encoding Valpha and/or Vbeta regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprises chimeric proteins made specifically from particular T cells from a patient having T cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a T cell mediated pathology.

Provided is a method for preparing a conjugate by linking a physiologically active polypeptide, a non-peptidyl polymer linker, and an immunoglobulin constant region via a covalent bond. The method for efficiently preparing the physiologically active polypeptide conjugate uses a salt in a coupling reaction to solve the problem of low production yield during preparation of the physiologically active polypeptide conjugate. The conjugate of physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region can be produced with high purity and yield by the subject method. Due to the method for preparing the physiologically active polypeptide conjugate, production costs can be reduced. Therefore, the method can be used to develop long-acting formulations of physiologically active polypeptides, which have improved industrial applicability and drug regulation compliance.

Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.

Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance.

The present invention relates to biotechnology, belongs to the field of recombinant gene engineering, and is six kinds of humanized fused immunoglobulins prepared through recombinant gene engineering and cell culturing process and capable of recognizing and combining with vascular endothelial cell growth factor specifically and their application. These six kinds of fused immunoglobulins feature that each of them has immunoglobulin-like structure regions capable of being combined with VEGF in the N-end and human immunoglobulin constant region in the C-end. These fused immunoglobulins have the bioactivity of high combination with VEGF and the bioactivity of immunoglobulin constant region, and can neutralize the VEGF inside adsorbed body to antagonize and inhibit fission and proliferation of vascular endothelial cell. These fused immunoglobulins are applied as VEGF neutralizing adsorbent alone or in combination.

The invention discloses fusion protein of thymulin alpha1. The fusion protein is formed by connecting the thymulin alpha1 or active fragments of the thymulin alpha1with a constant region of immune globulin through connecting peptide or directly. The fusion protein can be expressed in eukaryotic cells and can also be expressed in prokaryotic cells. According to the fusion protein of the thymulin alpha1, a pronucleus carrier containing a target gene is prepared through the recombination DAN technology and expressed, separated and purified in escherichia coli, and compared with archetype thymulin alpha1, the obtained fusion protein of the thymulin alpha1 is longer in in-vivo half-life period and more efficient in anti-tumor effect.

The invention provides an application of a urine immunoglobulin kappa constant region (IGKC) and a polypeptide fragment of the IGKC, and particularly relates to an application of a urine IGKC protein and a polypeptide fragment of the IGKC protein in preparation of a preparation for monitoring normal pregnancy or gestational diabetes mellitus. Researches prove that compared with a normal childbearing age woman group (normal control), the expression of IGKC and polypeptide fragments thereof in normal pregnancy and gestational diabetes mellitus groups is increased, and the IGKC and polypeptide fragments thereof can be used for monitoring and auxiliary diagnosis of gestational state or gestational diabetes mellitus patients. According to the invention, the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of a urine sample are exerted, and the urine IGKC protein and the polypeptide fragment thereof are detected by using the urine sample.